Relay Therapeutics, Inc.
RLAY Healthcare Biotechnology
In the quarter to June 2026, revenue fell 95.4%, EPS was flat and free cash flow grew 2.13%, each against the same quarter a year earlier.
Follow RLAY
Relay Therapeutics, Inc. (RLAY) EV/Sales
As of 16 October 2026, Relay Therapeutics, Inc. (RLAY) trades at a EV/Sales of 217×. Over the past ten years it has ranged from −11.1× (March 2025) to 1,274× (September 2022); the current reading is higher than 68% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 35.4× | — |
| FY2024 | −5.5× | — |
| FY2023 | 27.5× | (94.48%) |
| FY2022 | 499× | (23.03%) |
| FY2021 | 648× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 262× | 318.47% |
| Mar 2026 | 62.5× | 76.73% |
| Dec 2025 | 35.4× | — |
| Jun 2025 | −3.5× | — |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | n/m |
| EWTX Edgewise Therapeutics, Inc. compare | n/m |
| VKTX Viking Therapeutics, Inc. compare | n/m |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 2.2× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 4.3× |
| ARQT Arcutis Biotherapeutics, Inc. compare | 7.8× |
| TNGX Tango Therapeutics, Inc. compare | 36.7× |
| ABCL AbCellera Biologics Inc. compare | 46.0× |
| RLAY Relay Therapeutics, Inc. | 217× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)